Today's Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point
Published Date: 14 Oct 2026

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Read More
Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD
Published Date: 14 Oct 2026

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

Read More
NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH
Published Date: 14 Oct 2026

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Read More
Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD
Published Date: 14 Oct 2026

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

Read More
ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC
Published Date: 14 Oct 2026

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Read More
Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC
Published Date: 14 Oct 2026

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Read More
Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD
Published Date: 14 Oct 2026

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Read More
Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes
Published Date: 14 Oct 2026

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Read More
FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?
Published Date: 14 Oct 2026

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

Read More
Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD
Published Date: 14 Oct 2026

An ARCADIA investigator says patients in practice match the 3-year trial results and outlines next steps for IL-31 research.

Read More
No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH Christina Chambers, PhD, MPH
Published Date: 14 Oct 2026

Chambers discusses final results from a 7-year dupilumab pregnancy registry showing no evidence of increased risk for major birth defects or other outcomes.

Read More
Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD Iltefat Hamzavi, MD
Published Date: 14 Oct 2026

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Read More
Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD
Published Date: 14 Oct 2026

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Read More
Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?
Published Date: 14 Oct 2026

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Read More

Latest News


Latest News

News All Time


Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.

2.

When BCG is not effective in treating bladder cancer, Oncolytic Virus exhibits high response rates.

3.

Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?

4.

Urinary tract cancer prediction models with high sensitivity and specificity

5.

Mapping lifelong chronic health risks for childhood cancer survivors



© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot